click below
click below
Normal Size Small Size show me how
IOS6 exam3
Pharmacology of Cancer Drugs
| Question | Answer |
|---|---|
| Mechanism of resistance of alkylating agents | Decreased permeation of actively transported drugs, increased activity of DNA repair enzymes, increased glutathione, increased rate of metabolism (cyclophosphamide) |
| Method used to deplete glutathione and thus overcome one mechanism of resistance to alkylating agents... | buthionine sulfoximine (BSO) |
| Toxicities of alkylating agents | leukemogenic, bone marrow suppression, toxic to intestinal mucosa (lesser exent), pulmonary fibrosis, endothelial damage (at high doses) |
| MOA of platinum compounds | Exact mechanism unknow, but they form DNA adducts |
| Major mechanism of resistance to platinum compounds | DNA repair enzymes |
| Cisplatin uses and toxicities | Broad activity useful in epithelial malignanciesrenal proximal tubular necrosis, ototoxicity |
| Carboplatin uses and toxicities | Used for ovarian cancerrenal proximal tubular necrosis, ototoxicity (less than cisplatin) |
| Oxaliplatin uses | Ovarian and cervical cancer (more effective than other 2 platinum compounds because DNA repair enzyme proficient cells are equally effective). |
| MOA of antimetabolites | Interfere with DNA synthesis (S phase) |
| MOA of methotrexate (antimetabolite) | Dihydrofolate reductase inhibitor thus blocking the regeneration of tetrahydrofolate, and also inhibits folate dependent enzyme of purine and thymidine synthesis |
| MOA of pemetrexed (antimetabolite) | Inhibits thymidylate and purine biosynthesis in addition to dihydrofolate reductase. |